|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.08 - 5.24|
|52 Week Range||3.67 - 7.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This prospective upside marks the maximum quarterly earnings growth pace in seven years. The report further predicts that 11 of the 16 Zacks sectors are projected to exhibit double-digit earnings growth in the to-be-reported quarter.
Aratana Therapeutics (PETX) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Aratana Therapeutics Inc (NASDAQ: PETX ), which has a portfolio treatments for pet diseases and disorders, is likely to ride high on product momentum, according to Stifel. The Analyst Analyst Jonathan ...
The funds were raised through the sale of 2.39 million shares via an at-the-market sales agreement with Cowen and Co. LLC. The agreement, which Aratana (PETX) entered in December, would allow the company incrementally to sell up to $50 million worth of shares. Considering the most recent sales, Aratana may sell the remaining $38 million in stock.
Aratana Therapeutics Inc., a Leawood-based animal health company (Nasdaq: PETX), raised $11.7 million through a stock sales agreement.
On a per-share basis, the Leawood, Kansas-based company said it had a loss of 37 cents. Losses, adjusted for asset impairment costs, came to 19 cents per share. The results surpassed Wall Street expectations. ...
Aratana Therapeutics Inc’s (NASDAQ:PETX): Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium.Read More...
Aratana Therapeutics (NASDAQ: PETX ) announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue Analysts covering ...
Aratana Therapeutics Inc. bought exclusive rights to develop a pain and inflammation treatment from Japanese drug developer AskAt Inc. The deal is part of a broader research-and-development agreement Aratana launched with AskAt. The partnership will stock Aratana's pipeline with human health compounds developed by AskAt that have the potential to treat pain, allergies and cancer in animals.
Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.
Two specialized small-cap drug developers, and a financial holding company share similar traits to software giant Microsoft from three decades ago.
Kansas and Missouri have just a few months until funding for children's health insurance runs dry. Congress has not yet renewed funding for the Children's Health Insurance Program (CHIP), which provides coverage to about 79,000 kids in Kansas and 88,000 in Missouri. The program provides more matching federal money to states than Medicaid, and it covers health insurance for children whose families make too much to qualify for Medicaid but still don’t have access to private insurance.
Aratana Therapeutics Inc.'s newest treatment for dogs failed an effectiveness study, the Leawood animal health company announced Friday. Its latest drug candidate, a fat-derived stem cell treatment, was intended to treat dogs with advanced osteoarthritis. The treatment, dubbed AT-016, had entered pivotal trials, meaning the data would be used as evidence for approval by the Food and Drug Administration.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aratana Therapeutics, Inc. Here are 5 ETFs with the largest exposure to PETX-US. Comparing the performance and risk of Aratana Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
With its third FDA-approved drug on the market, Aratana Therapeutics is hunting its next product, a canine cancer immunotherapy treatment. The treatment, called AT-014, would be used to treat bone cancer, or osteosarcoma, in dogs. Aratana (PETX) expects to obtain conditional licensure for the treatment from the U.S. Department of Agriculture before the end of 2017, which would allow the company to launch a safety study within a group of veterinary oncologists.
Categories: Yahoo FinanceGet free summary analysis Aratana Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aratana Therapeutics, Inc. – Zoetis, Inc. Class A, Eli Lilly and Company, Heska Corporation and Merck & Co., Inc. (ZTS-US, LLY-US, HSKA-US and MRK-US) that have also reported ... Read more (Read more...)
On a per-share basis, the Leawood, Kansas-based company said it had a loss of 21 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...